---
document_datetime: 2023-09-21 18:08:23
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/revatio-epar-procedural-steps-taken-authorisation_en.pdf
document_name: revatio-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5377125
conversion_datetime: 2025-12-21 11:44:26.825182
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant Pfizer Limited submitted on  2  December  2004  an  application for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for REVATIO,  which  was  designated  as  an  orphan  medicinal  product  EU/3/03/178  on  12  December 2003.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Dr. Frits Lekkerkerker Co-Rapporteur: Prof. Fernando de Andres-Trelles

## Orphan Drugs:

REVATIO was designated as an orphan medicinal  product in  the  following  condition:    pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The calculated prevalence of this condition was 1 per 10,000 EU population.

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No  847/2000,  the  application  contained  a  critical  report  addressing  the  possible  similarity  with authorised orphan medicinal products.

## Scientific Advice:

The applicant did not seek scientific advice at the CHMP.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 25 November 2004.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 28 February 2005. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 1 March 2005.
- The procedure started on 20 December 2004.
- The CHMP adopted a report on similarity of Revatio with Tracleer and Ventavis on 17 March 2005.
- During  the  meeting  on  18  -  21  April  2005,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  20 April 2005.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 10 May 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  30 June 2005.
- Following receipt of applicant written clarifications on 14 July 2005, the Rapporteurs circulated an updated Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  22 July 2005 .
- During the meeting on  25-28 July 2005, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  under  exceptional  circumstances  to  Revatio  on  27  July  2005.  The applicant provided the letter of undertaking on the specific obligations and follow-up measures to be fulfilled post-authorisation on 27 July 2005.

<div style=\"page-break-after: always\"></div>

- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 28 October 2005.